HRP20190461T1 - Čvrsti pripravak koji sadrži željezo, namijenjen upotrebi kod stanja s nedostatkom željeza - Google Patents
Čvrsti pripravak koji sadrži željezo, namijenjen upotrebi kod stanja s nedostatkom željeza Download PDFInfo
- Publication number
- HRP20190461T1 HRP20190461T1 HRP20190461TT HRP20190461T HRP20190461T1 HR P20190461 T1 HRP20190461 T1 HR P20190461T1 HR P20190461T T HRP20190461T T HR P20190461TT HR P20190461 T HRP20190461 T HR P20190461T HR P20190461 T1 HRP20190461 T1 HR P20190461T1
- Authority
- HR
- Croatia
- Prior art keywords
- weight
- intended
- accordance
- amount ranging
- iron
- Prior art date
Links
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 title 4
- 229910052742 iron Inorganic materials 0.000 title 2
- 230000002950 deficient Effects 0.000 title 1
- 239000008247 solid mixture Substances 0.000 title 1
- 235000010445 lecithin Nutrition 0.000 claims 10
- 239000000787 lecithin Substances 0.000 claims 10
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims 8
- 229940067606 lecithin Drugs 0.000 claims 8
- VTLYFUHAOXGGBS-UHFFFAOYSA-N Fe3+ Chemical class [Fe+3] VTLYFUHAOXGGBS-UHFFFAOYSA-N 0.000 claims 7
- 150000003445 sucroses Chemical class 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims 4
- 239000001959 sucrose esters of fatty acids Substances 0.000 claims 4
- 230000000153 supplemental effect Effects 0.000 claims 4
- CADNYOZXMIKYPR-UHFFFAOYSA-B ferric pyrophosphate Chemical compound [Fe+3].[Fe+3].[Fe+3].[Fe+3].[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O CADNYOZXMIKYPR-UHFFFAOYSA-B 0.000 claims 3
- 239000007787 solid Substances 0.000 claims 3
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 claims 2
- 102000008857 Ferritin Human genes 0.000 claims 2
- 238000008416 Ferritin Methods 0.000 claims 2
- 108050000784 Ferritin Proteins 0.000 claims 2
- 241000208818 Helianthus Species 0.000 claims 2
- 235000003222 Helianthus annuus Nutrition 0.000 claims 2
- 102000001554 Hemoglobins Human genes 0.000 claims 2
- 108010054147 Hemoglobins Proteins 0.000 claims 2
- 206010022971 Iron Deficiencies Diseases 0.000 claims 2
- 229920000881 Modified starch Polymers 0.000 claims 2
- 229930006000 Sucrose Natural products 0.000 claims 2
- 240000008042 Zea mays Species 0.000 claims 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims 2
- 208000007502 anemia Diseases 0.000 claims 2
- 235000005822 corn Nutrition 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 235000007144 ferric diphosphate Nutrition 0.000 claims 2
- 239000011706 ferric diphosphate Substances 0.000 claims 2
- 229940036404 ferric pyrophosphate Drugs 0.000 claims 2
- 230000035935 pregnancy Effects 0.000 claims 2
- 229940100486 rice starch Drugs 0.000 claims 2
- 239000008347 soybean phospholipid Substances 0.000 claims 2
- 239000005720 sucrose Substances 0.000 claims 2
- -1 sucrose ester Chemical class 0.000 claims 2
- 229920002261 Corn starch Polymers 0.000 claims 1
- 229920002472 Starch Polymers 0.000 claims 1
- 239000008120 corn starch Substances 0.000 claims 1
- 230000008774 maternal effect Effects 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 239000000843 powder Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000008107 starch Substances 0.000 claims 1
- 235000019698 starch Nutrition 0.000 claims 1
- 229940005741 sunflower lecithin Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Pretreatment Of Seeds And Plants (AREA)
Claims (14)
1. Čvrsti pripravak namijenjen upotrebi u liječenju poremećaja ili bolesti povezanih s nedostatkom željeza, naznačen time što sadrži:
(i) sol željeza(III), koja je feri pirofosfat, u količini koja se kreće od 30 do 70 %, težinski; i
(ii) estere saharoze ili saharoestere E473, u količini koja se kreće od 10 do 30 %, težinski; i
(iii) lecitin, koji je lecitin E322, gdje se navedeni lecitin bira iz skupine koju čine kukuruzni, suncokretov ili sojin lecitin; i u količini je koja se kreće od 0,1 do 1,5 %, težinski.
2. Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što navedeni pripravak dodatno sadrži želatinirani ili preželatinirani škrob.
3. Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što se navedeni pripravak sastoji od:
(i) soli željeza(III), koja je feri pirofosfat, u količini koja se kreće od 30 do 70 %, težinski; i
(ii) estera saharoze ili saharoestera E473, u količini koja se kreće od 10 do 30 %, težinski; i
(iii) lecitina, koji je lecitin E322, gdje se navedeni lecitin bira iz skupine koju čine kukuruzni, suncokretov ili sojin lecitin; i u količini je koja se kreće od 0,1 do 1,5 %, težinski.
4. Pripravak namijenjen upotrebi u skladu s patentnim zahtjevima 1-3, naznačen time što je navedena sol željeza(III) u količini koja se kreće od 40 do 60 %, težinski.
5. Pripravak namijenjen upotrebi u skladu s patentnim zahtjevima 1-4, naznačen time što su navedeni esteri saharoze ili saharoesteri E473 u količini koja se kreće od 15 do 25 %, težinski.
6. Pripravak namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1-5, naznačen time što je navedeni lecitin u količini koja se kreće od 0,4 do 1 %, težinski.
7. Pripravak namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1-6, naznačen time što su navedeni esteri saharoze ili saharoesteri i navedeni lecitin u pripravku u težinskom omjeru koji se kreće od 25:1 do 20:1; po mogućnosti u težinskom omjeru koji se kreće od 20:1 do 15:1.
8. Pripravak namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1-2 ili 4-6, naznačen time što se navedeni želatinirani ili preželatinirani škrob bira iz skupine koju čine rižin škrob ili kukuruzni škrob; gdje je navedeni škrob u količini koja se kreće od 15 do 40 %, težinski, po mogućnosti od 20 do 35 %, težinski.
9. Pripravak namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1-2 ili 4-8, naznačen time što je željezni pirofosfat u količini koja se kreće od 50 do 55 %, težinski; lecitin iz suncokreta je u količini koja se kreće od 0,5 do 0,8 %, težinski; saharoester E473 je u količini koja se kreće od 16 do 20 %, težinski; želatinirani ili preželatinirani rižin škrob je u količini koja se kreće od 25 do 30 %, težinski.
10. Pripravak namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1-9, naznačen time što navedeni čvrsti pripravak namijenjen oralnoj upotrebi ima veličinu čestica koja se kreće od 8 do 16 µm, po mogućnosti od 10 do 14 µm; gustoću praha koja se kreće od 0,3 do 0,8 g/ml, po mogućnosti od 0,4 do 0,7 g/ml i sadržaj željeza(III) koji se kreće od 60 mg/g do 140 mg/g, po mogućnosti od 80 mg/g do 120 mg/g, još poželjnije od 90 do 110 mg/g.
11. Suplementni proizvod ili medicinski uređaj ili farmaceutski pripravak namijenjen oralnoj upotrebi, naznačeni time što sadrže čvrsti pripravak namijenjen oralnoj upotrebi u skladu s bilo kojim od patentnih zahtjeva 1-10 namijenjen upotrebi u liječenju poremećaja ili bolesti povezanih s nedostatkom željeza kod pedijatrijskih subjekata, adolescenata, sportaša, muškaraca, žena, trudnica i starijih osoba.
12. Suplementni proizvod ili medicinski uređaj ili farmaceutski pripravak u skladu s patentnim zahtjevom 11, naznačeni time što su namijenjeni upotrebi kod pedijatrijskih subjekata, adolescenata, sportaša, muškaraca, žena i starijih osoba radi sprječavanja anemije i povećavanje vrijednosti hemoglobina i feritina; ili što su namijenjeni upotrebi kod trudnica radi povećavanja porođajne težine novorođenčeta, sprječavanja majčinske anemije i povećavanja vrijednosti hemoglobina i feritina i tijekom trudnoće i nakon poroda.
13. Suplementni proizvod ili medicinski uređaj ili farmaceutski pripravak u skladu s patentnim zahtjevima 11 i 12, naznačeni time što su namijenjeni upotrebi kod pedijatrijskih subjekata, adolescenata, sportaša, muškaraca, žena i starijih osoba u periodu koji se kreće od 1 do 5 mjeseci, po mogućnosti od 2 do 4 mjeseca; ili što su namijenjeni upotrebi kod trudnica radi primjene kroz period trudnoće, osobito od 12. tjedna do 6 tjedana nakon poroda.
14. Suplementni proizvod ili medicinski uređaj ili farmaceutski pripravak u skladu s patentnim zahtjevima 11-13, naznačeni time što su namijenjeni upotrebi kod pedijatrijskih subjekata, adolescenata, sportaša, muškaraca, žena, trudnica i starijih osoba, u dozi koja se kreće od 10 do 40 mg željeza(III) dnevno, po mogućnosti od 14 do 30 mg željeza(III) dnevno, još poželjnije 28 mg željeza(III) dnevno.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT001350A ITMI20121350A1 (it) | 2012-07-31 | 2012-07-31 | Composizione solido a base di ferro per uso nelle condizioni di deficienza di ferro. |
| PCT/IB2013/001659 WO2014009806A1 (en) | 2012-07-31 | 2013-07-30 | Solid composition comprising iron for use in iron deficient conditions |
| EP13777110.1A EP2879667B1 (en) | 2012-07-31 | 2013-07-30 | Solid composition comprising iron for use in iron deficient conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20190461T1 true HRP20190461T1 (hr) | 2019-06-14 |
Family
ID=46982695
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20190461TT HRP20190461T1 (hr) | 2012-07-31 | 2019-03-08 | Čvrsti pripravak koji sadrži željezo, namijenjen upotrebi kod stanja s nedostatkom željeza |
| HRP20201802TT HRP20201802T1 (hr) | 2012-07-31 | 2020-11-11 | Kruti pripravak koji sadrži željezo za uporabu u uvjetima nedostatka željeza |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201802TT HRP20201802T1 (hr) | 2012-07-31 | 2020-11-11 | Kruti pripravak koji sadrži željezo za uporabu u uvjetima nedostatka željeza |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US10183077B2 (hr) |
| EP (2) | EP3498265B1 (hr) |
| JP (1) | JP6232426B2 (hr) |
| CN (2) | CN111265546A (hr) |
| BR (2) | BR122022015143B1 (hr) |
| CA (1) | CA2879681C (hr) |
| CY (2) | CY1121435T1 (hr) |
| DK (2) | DK3498265T3 (hr) |
| EA (1) | EA027684B1 (hr) |
| ES (2) | ES2830428T3 (hr) |
| HR (2) | HRP20190461T1 (hr) |
| HU (2) | HUE042698T2 (hr) |
| IL (2) | IL236793A0 (hr) |
| IN (1) | IN2015MN00127A (hr) |
| IT (1) | ITMI20121350A1 (hr) |
| LT (2) | LT2879667T (hr) |
| MA (1) | MA20150375A1 (hr) |
| ME (1) | ME03349B (hr) |
| PL (2) | PL3498265T3 (hr) |
| PT (2) | PT2879667T (hr) |
| RS (2) | RS58647B1 (hr) |
| SI (2) | SI2879667T1 (hr) |
| TR (1) | TR201903899T4 (hr) |
| WO (1) | WO2014009806A1 (hr) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20121350A1 (it) | 2012-07-31 | 2014-02-01 | Alesco Srl | Composizione solido a base di ferro per uso nelle condizioni di deficienza di ferro. |
| ITMI20131483A1 (it) | 2013-09-09 | 2015-03-10 | Alesco Srl | Composizioni in forma solida a base di minerali e formulazioni orosolubili contenenti le stesse. |
| JP6299689B2 (ja) * | 2014-07-24 | 2018-03-28 | 三生医薬株式会社 | 生体吸収促進剤含有組成物 |
| JP6459129B2 (ja) * | 2015-04-13 | 2019-01-30 | 富田製薬株式会社 | ピロリン酸第二鉄含有粉末及びその製造方法 |
| WO2017090198A1 (ja) * | 2015-11-27 | 2017-06-01 | 太陽化学株式会社 | 鉄含有粉末組成物 |
| IT201700085412A1 (it) * | 2017-07-26 | 2019-01-26 | Pharmanutra S P A | Composizione per uso nella prevenzione e nel trattamento di patologie dell'apparato cardiovascolare |
| IT201700089258A1 (it) * | 2017-08-02 | 2019-02-02 | Pharmanutra S P A | Composizione per uso nella prevenzione e nel trattamento di carenza di ferro |
| IT201800006288A1 (it) * | 2018-06-13 | 2019-12-13 | Composizioni comprendenti minerali sucrosomiali contenenti sali minerali per uso nelle condizioni di deficienza di tali minerali | |
| IT201900020290A1 (it) | 2019-11-04 | 2021-05-04 | Alesco Srl | Berberina sucrosomiale®, sue composizioni e loro uso |
| IT201900020300A1 (it) | 2019-11-04 | 2021-05-04 | Alesco Srl | Uso di berberina sucrosomiale® e sue composizioni nel trattamento di dislipidemie |
| IT201900020316A1 (it) | 2019-11-04 | 2021-05-04 | Alesco Srl | Uso di berberina sucrosomiale® e sue composizioni nel trattamento di alterazioni del metabolismo glucidico |
| IT201900021564A1 (it) * | 2019-11-19 | 2021-05-19 | Neilos S R L | Composizione nutraceutica o farmaceutica comprendente ferro pirofosfato per l’uso nel trattamento e/o nella prevenzione di condizioni o patologie caratterizzate da carenza di ferro |
| IT201900022989A1 (it) | 2019-12-04 | 2021-06-04 | Alesco Srl | Formulazione in forma solida di cromo, sue composizioni e usi |
| IT201900023016A1 (it) * | 2019-12-04 | 2021-06-04 | Alesco Srl | Formulazioni comprendenti un minerale e un polisaccaride, loro composizioni e loro uso nella supplementazione di detto minerale |
| WO2022118274A1 (en) * | 2020-12-03 | 2022-06-09 | Neilos S.r.l. | Compositions for the use in the treatment and/or prevention of iron deficiency conditions or diseases |
| IT202100005981A1 (it) | 2021-03-12 | 2022-09-12 | Pharmanutra S P A | Composizione a base di ferro per uso in un trattamento di una infiammazione gastrointestinale in soggetti sottoposti ad un trattamento di una deficienza di ferro |
| IT202100011084A1 (it) | 2021-04-30 | 2022-10-30 | Pharmanutra S P A | Composizione nutraceutica per uso nel trattamento della stanchezza cronica/fatigue post covid-19 |
| WO2023033750A1 (en) * | 2021-08-30 | 2023-03-09 | Ilko Ilac Sanayi Ve Ticaret A.S. | Preservative free liquid formulation of lipozomal iron |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998011877A1 (en) * | 1996-09-18 | 1998-03-26 | Dragoco, Inc. | Liposome encapsulated active agent dry powder composition |
| WO1998014072A1 (fr) | 1996-10-03 | 1998-04-09 | Taiyo Kagaku Co., Ltd. | Composition minerale |
| JP2000300213A (ja) | 1999-04-21 | 2000-10-31 | Taiyo Kagaku Co Ltd | ミネラル組成物及びミネラル強化飲食品 |
| US6521247B1 (en) * | 1999-08-13 | 2003-02-18 | Warner Chilcott Laboratories Ireland Limited | Dual iron containing nutritional supplement |
| JP2007224054A (ja) * | 2004-02-02 | 2007-09-06 | Taiyo Kagaku Co Ltd | 鉄組成物 |
| JP4627999B2 (ja) * | 2004-02-27 | 2011-02-09 | 太陽化学株式会社 | 坑酸化剤 |
| WO2005082167A1 (en) * | 2004-02-27 | 2005-09-09 | Taiyo Kagaku Co., Ltd. | Minera-containing composition and method of use thereof |
| JP2006340613A (ja) * | 2005-06-07 | 2006-12-21 | Taiyo Kagaku Co Ltd | 鉄強化用組成物 |
| JP2006340612A (ja) * | 2005-06-07 | 2006-12-21 | Taiyo Kagaku Co Ltd | ミネラル強化用組成物 |
| WO2006137133A1 (ja) * | 2005-06-22 | 2006-12-28 | Taiyo Kagaku Co., Ltd. | 鉄強化用組成物 |
| DK1973552T3 (en) * | 2005-12-23 | 2017-08-07 | Ajay Gupta | Parenteral nutritional composition containing iron |
| JP4673235B2 (ja) * | 2006-02-16 | 2011-04-20 | 太陽化学株式会社 | 鉄強化食品用組成物 |
| EP2073821B1 (en) * | 2006-09-28 | 2012-10-24 | Bayer Consumer Care AG | Mixture of iron and copper salts masking metallic taste |
| KR101811376B1 (ko) * | 2010-06-09 | 2017-12-22 | 에미스페어 테크놀로지스, 인코포레이티드 | 경구용 철 결핍증 치료 |
| US20120288531A1 (en) * | 2011-01-14 | 2012-11-15 | Shmuel Tuvia | pharmaceutical compositions for delivery of ferric iron compounds, and methods of use thereof |
| ITMI20121350A1 (it) | 2012-07-31 | 2014-02-01 | Alesco Srl | Composizione solido a base di ferro per uso nelle condizioni di deficienza di ferro. |
| US9594814B2 (en) | 2012-09-07 | 2017-03-14 | Splunk Inc. | Advanced field extractor with modification of an extracted field |
-
2012
- 2012-07-31 IT IT001350A patent/ITMI20121350A1/it unknown
-
2013
- 2013-07-30 ME MEP-2019-76A patent/ME03349B/me unknown
- 2013-07-30 EA EA201590204A patent/EA027684B1/ru unknown
- 2013-07-30 DK DK19151902.4T patent/DK3498265T3/da active
- 2013-07-30 CN CN202010086252.6A patent/CN111265546A/zh active Pending
- 2013-07-30 EP EP19151902.4A patent/EP3498265B1/en active Active
- 2013-07-30 US US14/417,786 patent/US10183077B2/en active Active
- 2013-07-30 JP JP2015524859A patent/JP6232426B2/ja active Active
- 2013-07-30 PL PL19151902T patent/PL3498265T3/pl unknown
- 2013-07-30 PL PL13777110T patent/PL2879667T3/pl unknown
- 2013-07-30 PT PT13777110T patent/PT2879667T/pt unknown
- 2013-07-30 DK DK13777110.1T patent/DK2879667T3/en active
- 2013-07-30 CA CA2879681A patent/CA2879681C/en active Active
- 2013-07-30 ES ES19151902T patent/ES2830428T3/es active Active
- 2013-07-30 LT LTEP13777110.1T patent/LT2879667T/lt unknown
- 2013-07-30 WO PCT/IB2013/001659 patent/WO2014009806A1/en active Application Filing
- 2013-07-30 RS RS20190389A patent/RS58647B1/sr unknown
- 2013-07-30 PT PT191519024T patent/PT3498265T/pt unknown
- 2013-07-30 BR BR122022015143-4A patent/BR122022015143B1/pt active IP Right Grant
- 2013-07-30 TR TR2019/03899T patent/TR201903899T4/tr unknown
- 2013-07-30 CN CN201380040500.1A patent/CN104602674A/zh active Pending
- 2013-07-30 HU HUE13777110A patent/HUE042698T2/hu unknown
- 2013-07-30 LT LTEP19151902.4T patent/LT3498265T/lt unknown
- 2013-07-30 IN IN127MUN2015 patent/IN2015MN00127A/en unknown
- 2013-07-30 HU HUE19151902A patent/HUE052036T2/hu unknown
- 2013-07-30 SI SI201331383T patent/SI2879667T1/sl unknown
- 2013-07-30 RS RS20201271A patent/RS61069B1/sr unknown
- 2013-07-30 SI SI201331815T patent/SI3498265T1/sl unknown
- 2013-07-30 ES ES13777110T patent/ES2719252T3/es active Active
- 2013-07-30 MA MA37814A patent/MA20150375A1/fr unknown
- 2013-07-30 EP EP13777110.1A patent/EP2879667B1/en active Active
- 2013-07-30 BR BR112015002072-0A patent/BR112015002072B1/pt active IP Right Grant
-
2015
- 2015-01-19 IL IL236793A patent/IL236793A0/en active IP Right Grant
-
2018
- 2018-12-11 US US16/216,432 patent/US10765752B2/en active Active
-
2019
- 2019-03-08 HR HRP20190461TT patent/HRP20190461T1/hr unknown
- 2019-03-15 CY CY20191100311T patent/CY1121435T1/el unknown
- 2019-03-24 IL IL265561A patent/IL265561B/en active IP Right Grant
-
2020
- 2020-11-06 CY CY20201101049T patent/CY1123610T1/el unknown
- 2020-11-11 HR HRP20201802TT patent/HRP20201802T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20190461T1 (hr) | Čvrsti pripravak koji sadrži željezo, namijenjen upotrebi kod stanja s nedostatkom željeza | |
| Huang et al. | Effects of nano calcium carbonate and nano calcium citrate on toxicity in ICR mice and on bone mineral density in an ovariectomized mice model | |
| ES2609654T3 (es) | Composición nutritiva para promover la salud del aparato locomotor de pacientes que sufren la enfermedad del intestino inflamatorio (IBD) | |
| CN105410943B (zh) | 一种复合维生素片及其制备方法 | |
| ES2927216T3 (es) | Una composición farmacéutica para la anemia | |
| HRP20240115T1 (hr) | Povećavanje bioraspoloživosti lijeka u terapiji naltreksonom | |
| JP2015529234A5 (hr) | ||
| ECSP15042897A (es) | Formulaciones orales de deferasirox | |
| JP2013541595A5 (hr) | ||
| TR201818761T4 (tr) | 4-amino-5-floro-3-[6-(4-metilpiperazin-1-il)-1h-benzimidazol-2-il]-1h-kinolin-2-on laktat monohidrat içeren farmasötik bileşimler. | |
| JP2010527347A5 (hr) | ||
| JP2012236834A5 (hr) | ||
| JP2015505295A5 (hr) | ||
| JP2011510922A5 (hr) | ||
| JP6512099B2 (ja) | 錠剤組成物 | |
| JP2006523642A5 (hr) | ||
| PT2908828T (pt) | Composições galactagogas à base de fosfatidilserina | |
| MY171963A (en) | Nutritional composition comprising whey and hydrolyzed casein and uses thereof | |
| CA2925188C (en) | Solid compositions based on minerals and orally disintegrating formulations containing the same | |
| JP6662678B2 (ja) | 癌細胞増殖抑制組成物 | |
| RU2014146562A (ru) | Композиция, содержащая альфа-липоевую кислоту и гонокиол, для лечения нейропатий | |
| JP3604710B2 (ja) | 骨粗鬆症予防及び治療剤 | |
| JP2015533484A5 (hr) | ||
| JP2015507002A5 (hr) | ||
| IT201900008394A1 (it) | Composizione per uso nel trattamento delle malattie infiammatorie croniche intestinali |